Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis

Phase II Study Intravitreally Admininstered Ranibizumab in 50 Subjects With AMD Having Received at Least 3 Doses of Intermittent Anti-VEGF Therapy in the Preceding 18 Months

The purpose of this study is to determine whether people who have received intermittent anti-VEGF therapy have an improvement in vision after being switched to monthly injections of Lucentis.

To determine mean change in visual acuity at 6 and 12 months

Inclusion Criteria:

• Ability to provide written informed consent and comply with study assessments for the full duration of the study
• Age greater then and equal 50 years
• Patients with active neovascular AMD
• Received at least 3 treatments with anti-VEGF therapy (bevacizumab or pegaptanib or ranibizumab) in the last 24 months
• If the patient has bilateral disease and qualifies for the study, both eyes may be included

Exclusion Criteria:

• Subjects who meet any of the following criteria will be excluded from this study:
• Pregnancy or lactation
• Premenopausal women not using adequate contraception.
• Participation in another simultaneous medical investigation